Plasmocitoma extramedular de afectación colónica: experiencia en un hospital del tercer nivel

Mesa López, María José; Salazar Nicolás, Alejandro; Leal Rubio, Juan Diego; Muñoz Tornero, María; Egea Valenzuela, Juan.
Rev. esp. enferm. dig ; 114(10): 629-630, octubre 2022. ilus
Artículo en Español | IBECS (España) | ID: ibc-210786

Documentos relacionados

  1. Extramedullary plasmacytoma with colonic involvement: experience in a tertiary hospital.
  2. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
  3. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
  4. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
  5. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.
  6. Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
  7. Four-Drug Therapy for Multiple Myeloma. Reply.
  8. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
  9. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
  10. Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations.